Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of “Moderate Buy” from Analysts

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been assigned a consensus rating of “Moderate Buy” from the twelve brokerages that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $42.00.

Several analysts recently commented on the company. Weiss Ratings downgraded Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Wedbush boosted their target price on Stoke Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Tuesday, March 17th. Wall Street Zen downgraded Stoke Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Chardan Capital reaffirmed a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 18th. Finally, Needham & Company LLC lifted their price objective on Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, March 17th.

Insider Activity at Stoke Therapeutics

In other news, insider Barry Ticho sold 1,795 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $30.58, for a total value of $54,891.10. Following the completion of the transaction, the insider owned 34,826 shares in the company, valued at $1,064,979.08. This represents a 4.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $29.95, for a total transaction of $43,637.15. Following the sale, the general counsel owned 18,086 shares in the company, valued at approximately $541,675.70. The trade was a 7.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.60% of the stock is owned by corporate insiders.

Institutional Trading of Stoke Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Kestra Advisory Services LLC acquired a new stake in Stoke Therapeutics in the 4th quarter valued at approximately $26,000. KBC Group NV bought a new position in shares of Stoke Therapeutics during the 1st quarter worth approximately $36,000. Harbour Investments Inc. raised its holdings in shares of Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after purchasing an additional 898 shares during the last quarter. Western Wealth Management LLC acquired a new stake in shares of Stoke Therapeutics in the first quarter valued at approximately $55,000. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Stoke Therapeutics by 195.3% in the first quarter. EverSource Wealth Advisors LLC now owns 1,837 shares of the company’s stock worth $60,000 after purchasing an additional 1,215 shares in the last quarter.

Stoke Therapeutics Stock Down 1.1%

Shares of Stoke Therapeutics stock opened at $29.13 on Friday. The business has a fifty day simple moving average of $30.90 and a 200 day simple moving average of $32.30. The stock has a market cap of $1.81 billion, a PE ratio of -10.37 and a beta of 1.17. Stoke Therapeutics has a 12 month low of $11.66 and a 12 month high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.01. The firm had revenue of $6.23 million for the quarter, compared to analyst estimates of $6.48 million. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%. Analysts expect that Stoke Therapeutics will post -3.22 EPS for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.